FEMY - Femasys Inc. to Participate in The Post-Roe Fertility Journey Panel Discussion at SXSW 2023
ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced today that Kathy Lee-Sepsick, founder, president & chief executive officer, will participate in the South By Southwest (SXSW) 2023 Conference being held in Austin, Texas from March 10-19, 2023.
Kathy Lee-Sepsick will participate in a panel discussion titled “The Post-Roe Fertility Journey” on March 11, 2023 at 10:00 am CT, which will discuss what considerations are needed in women’s health for protection during fertility management and family building in the post-Roe era.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc ® permanent birth control and FemaSeed ® localized directional insemination for infertility. The Company’s products currently marketed in the United States, include FemVue ® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath ™ , an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv ® , an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn .
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com